gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · UTHRHealthcarePharmaceuticals

United Therapeutics Corp (UTHR)

$608.49+1.19%
Close Nov 4, 2026 · split-adjusted
Nov 2, 2026$596.13▲ 35.90% in range
Nov 3, 2025Low $437.33 · High $598.72Nov 2, 2026
What changed · written from our data
As of Nov 4, 2026

United Therapeutics closed at $608.49 on Nov 4, up 1.19% — matching its 52-week closing high. Volume of 946.8K shares was 1.48× its 20-day average (above normal).

Split-adjusted performance: +12.3% over one month, +2.0% over six months, +38.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $783.30M, down 1.9% from a year earlier, with a net margin of 42.5%.

Short interest was 2.5M shares at the Oct 15 settlement, down 31.7% from the prior report (5.9% of float, 2.6 days to cover).

Market cap$26.10B42.9M shares
Revenue · quarter$783.3M−1.9% YoY
Diluted EPS$7.27+13.4% YoY
P/E · TTM19.9×P/S 8.3×
Net margin42.5%Gross 87.3%
Dividend yieldNone
52-week range437.33 – 608.490.0% from high
Volume946.8K1.48× 20-day avg
Volatility · 60d37.1%Annualised
Short % of float5.9%2.6 days to cover
Net cash$2.66BCash $2.66B
Next earnings—Not scheduled
Split-adjusted performance
1W +3.8%1M +12.3%3M +14.2%6M +2.0%YTD +24.9%1Y +38.7%3Y +175.8%5Y +226.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum73
Revenue growth39
Net margin92
Value (low P/E)43
Size97

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short2.5M−31.7% vs prior
Days to cover2.6Settled Oct 15
% of float5.9%
Short vol. 10d55.5%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
UTHRUnited Therapeutics$608.49+1.19%+2.0%−1.9%42.5%19.9$26.10B
ROIVRoivant Sciences$38.23+6.08%+32.7%−33.5%−13164.8%—$27.61BCompare
INSMInsmed$110.00+5.32%−19.8%+268.4%−19.1%—$24.13BCompare
RPRXRoyalty Pharma$67.56+1.75%+33.2%+16.5%2.7%36.9$30.08BCompare
VTRSViatris$19.22+1.59%+20.5%+4.9%−3.2%—$22.08BCompare
ALNYAlnylam Pharmaceuticals$161.08+0.74%−46.8%+16.7%148.6%7.9$21.57BCompare
ZTSZOETIS$89.20+7.48%−19.8%−0.2%28.0%14.1$36.86BCompare
JAZZJazz Pharmaceuticals$234.66+2.14%+2.7%+10.4%−38.9%74.0$15.23BCompare
BBIOBridgeBio Pharma$77.89+5.21%+14.4%+192.6%−23.5%—$15.17BCompare

News about United Therapeutics

All news →
SGIOY vs. UTHR: Which Stock Is the Better Value Option?Zacks Investment Research · 5d agoNeutralLQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia LabelZacks Investment Research · Oct 14, 2026▲ PositiveSGIOY or UTHR: Which Is the Better Value Stock Right Now?Zacks Investment Research · Oct 14, 2026NeutralLiquidia Stock Plunges 57% on UTHR Patent Litigation SetbackZacks Investment Research · Oct 1, 2026▲ PositiveUTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%Zacks Investment Research · Oct 1, 2026▲ Positive

Quick answers

What does United Therapeutics do?
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil.
What is UTHR's market cap?
$26.10B, based on the Nov 4 close of $608.49.
What is UTHR's P/E ratio?
19.9× trailing-twelve-month earnings of $1.31B.
Does United Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of UTHR is sold short?
2.5M shares, 5.9% of float, as of Oct 15, 2026.
What sector is UTHR in?
Healthcare, in the Pharmaceuticals industry.

About United Therapeutics

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

HQ: Silver Spring, MD1,400 employeesListed Jun 17, 1999unither.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology